Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr Michael Rosenblatt joins Merck & Co

This article was originally published in Scrip

Executive Summary

Dr Michael Rosenblatt has been named executive vice-president and chief medical officer at Merck & Co. He will report directly to Merck's chairman, president and CEO, Richard Clark, will serve on the company’s executive committee and will oversee the company's global centre for scientific affairs. Dr Rosenblatt has served as dean of Tufts University School of Medicine since 2003. Before that, he was George R Minot Professor of Medicine at Harvard Medical School and chief of the division of bone and mineral metabolism research at Beth Israel Deaconess Medical Center.

You may also be interested in...



Flagship Ventures Tempts Former Merck CMO With 'Creative' Mentoring Role

Flagship Ventures has recruited former Merck Chief Medical Officer Michael Rosenblatt as its CMO to mentor biopharma startups in the venture firm's portfolio – a hire that appears to be the first of its kind.

Apobiologix Launches Pegfilgrastim Autoinjector In Canada

Apobiologix’s new Lapelga autoinjector that the firm has just introduced in Canada is only the second on-body pegfilgrastim device to launch after Amgen’s Neulasta original.

Regeneron ‘Shocked’ At Biogen Lucentis Biosimilar Sales

With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC006119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel